Immune cell surface glycoproteins

Immune cell surface glycoproteins are a vast and diverse group of proteins modified with carbohydrate chains that are expressed on the plasma membrane of various leukocytes, including T cells, B cells, and myeloid cells (NIH, 2023). These molecules serve as the primary interface between the immune cell and its environment, facilitating critical processes such as antigen recognition, cell-to-cell communication, and adhesion to vascular endothelium (Nature Reviews Immunology, 2021). Many of these glycoproteins are systematically classified under the Cluster of Differentiation (CD) nomenclature, which identifies specific markers like CD4, CD8, and CD20 (UniProt, 2024). In modern medicine, these proteins are among the most important therapeutic targets, particularly for monoclonal antibodies used in oncology and rheumatology (PubMed, 2022). For instance, targeting PD-1 or CTLA-4 can reinvigorate exhausted T cells to fight tumors, while targeting CD20 can deplete pathogenic B cells in lymphoma or autoimmunity (StatPearls, 2023). Because this term refers to a broad functional class of proteins rather than a single molecular entity, it is considered a category of targets rather than a specific therapeutic target itself.

Other names

Leukocyte surface antigensCD antigensCell surface markersImmune receptorsSurface glycoproteins of leukocytes

Mechanisms vary by specific target and include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), receptor antagonism, and immune checkpoint blockade (NIH, 2023).